BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema

Benha University

Status and phase: Unknown; Phase 3

Conditions: Macular Edema

Treatments: Drug: BEOVU intravitreal injection

Study type: Interventional

Funder types: Other

Identifiers

NCT04955171

Hamaky15

Details and patient eligibility

About

Diabetic macular edema degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management

Full description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab(BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea;Regeneron, Tarrytown,NY)

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diabetic macular edema

Exclusion criteria

• other causes of macular edema
• other macular diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

60 participants in 2 patient groups

BEOVU

Active Comparator group

Description:

Intravitreal injection of BEOVU 3 loading injections( monthly) then under treat and extent regimen

Treatment:

Drug: BEOVU intravitreal injection

Eylea

Active Comparator group

Description:

Intravitreal injection of Eylea 3 loading injections( monthly) then under treat and extent regimen

Treatment:

Drug: BEOVU intravitreal injection